User login
BALTIMORE – A cardioplegic solution developed by a noted cardiac surgeon has been deemed a “simple and safe” cardio protective strategy in a study presented at the annual meeting of the American Association for Thoracic Surgery.
In an interview at the event, Pedro J. del Nido, MD, chief of cardiac surgery at Boston Children’s Hospital, and inventor of the long-acting Del Nido solution, explained how and why he and his colleagues developed the new cardioplegic solution. He praised the study as uniquely important, given that there have been few prospective, randomized, and controlled comparative studies of cardioplegia targeted at pediatric patients.
“Baby hearts have a slightly different metabolism than adult hearts,” Dr. del Nido said. “Typically in pediatric procedures we not only cool the heart but we lower the whole body temperature... In the adult world we don’t drop the temperature so much.” He also said the method and flow rate of cardioplegia delivery was unique for pediatric patients, given the fragility of the endothelial cells lining their blood vessels.
The study compared the Del Nido solution with the St. Thomas cardioplegia solution. The investigators praised the Del Nido solution’s performance for “better cardiac index profile, lesser troponin-I release, and decreased morbidity.”
Dr. del Nido developed the Del Nido cardioplegic solution, but reported no other relevant financial disclosures.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @richpizzi
BALTIMORE – A cardioplegic solution developed by a noted cardiac surgeon has been deemed a “simple and safe” cardio protective strategy in a study presented at the annual meeting of the American Association for Thoracic Surgery.
In an interview at the event, Pedro J. del Nido, MD, chief of cardiac surgery at Boston Children’s Hospital, and inventor of the long-acting Del Nido solution, explained how and why he and his colleagues developed the new cardioplegic solution. He praised the study as uniquely important, given that there have been few prospective, randomized, and controlled comparative studies of cardioplegia targeted at pediatric patients.
“Baby hearts have a slightly different metabolism than adult hearts,” Dr. del Nido said. “Typically in pediatric procedures we not only cool the heart but we lower the whole body temperature... In the adult world we don’t drop the temperature so much.” He also said the method and flow rate of cardioplegia delivery was unique for pediatric patients, given the fragility of the endothelial cells lining their blood vessels.
The study compared the Del Nido solution with the St. Thomas cardioplegia solution. The investigators praised the Del Nido solution’s performance for “better cardiac index profile, lesser troponin-I release, and decreased morbidity.”
Dr. del Nido developed the Del Nido cardioplegic solution, but reported no other relevant financial disclosures.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @richpizzi
BALTIMORE – A cardioplegic solution developed by a noted cardiac surgeon has been deemed a “simple and safe” cardio protective strategy in a study presented at the annual meeting of the American Association for Thoracic Surgery.
In an interview at the event, Pedro J. del Nido, MD, chief of cardiac surgery at Boston Children’s Hospital, and inventor of the long-acting Del Nido solution, explained how and why he and his colleagues developed the new cardioplegic solution. He praised the study as uniquely important, given that there have been few prospective, randomized, and controlled comparative studies of cardioplegia targeted at pediatric patients.
“Baby hearts have a slightly different metabolism than adult hearts,” Dr. del Nido said. “Typically in pediatric procedures we not only cool the heart but we lower the whole body temperature... In the adult world we don’t drop the temperature so much.” He also said the method and flow rate of cardioplegia delivery was unique for pediatric patients, given the fragility of the endothelial cells lining their blood vessels.
The study compared the Del Nido solution with the St. Thomas cardioplegia solution. The investigators praised the Del Nido solution’s performance for “better cardiac index profile, lesser troponin-I release, and decreased morbidity.”
Dr. del Nido developed the Del Nido cardioplegic solution, but reported no other relevant financial disclosures.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @richpizzi
AT THE AATS ANNUAL MEETING
